Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

16. Juni 2021 08:00 ET | Quelle: Enlivex Therapeutics Ltd

Enlivex Annouces Participation in A.G.P.’s Upcoming 2021 Virtual Summer Healthcare Symposium

Nes Ziona, Israel, June 16, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
15. Juni 2021 08:00 ET | Quelle: Enlivex Therapeutics Ltd

Enlivex Announces Issuance of New European Patent Covering Therapeutic Compositions of Allocetra and CAR-T Immunotherapies for Inhibition or Reduction of Cytokine Storms Associated with CAR-T Therapies for Cancer

Nes-Ziona, Israel, June 15, 2021 (GLOBE NEWSWIRE) -- – Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased...
03. Juni 2021 08:00 ET | Quelle: Enlivex Therapeutics Ltd

Enlivex to Present at the Jefferies 2021 Virtual Healthcare Conference

Nes Ziona, Israel, June 03, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
01. Juni 2021 08:00 ET | Quelle: Enlivex Therapeutics Ltd

Enlivex Announces Issuance of New Canadian Patent Covering Pharmaceutical Compositions, Manufacturing Methods and Uses of Allocetra Immunotherapy

Nes-Ziona, Israel, June 01, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased...
18. Mai 2021 08:00 ET | Quelle: Enlivex Therapeutics Ltd

Enlivex Awarded Second Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis

Grant provides $1.1 million in non-dilutive funding for 2021 Nes Ziona, Israel, May 18, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage...
22. März 2021 08:00 ET | Quelle: Enlivex Therapeutics Ltd

Enlivex Announces Research Collaboration with Yale Cancer Center to Assess Synergistic Effect of Allocetra™ in Combination with Immune Checkpoint Inhibitors

Nes Ziona, Israel, March 22, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting...
09. März 2021 08:00 ET | Quelle: Enlivex Therapeutics Ltd

Enlivex Announces Upcoming Virtual Investor Conference Participations

Nes Ziona, Israel, March 09, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
08. März 2021 08:00 ET | Quelle: Enlivex Therapeutics Ltd

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the use of Allocetra in Combination with CAR-T Therapies

Nes-Ziona, Israel, March 08, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased...
01. März 2021 07:55 ET | Quelle: Enlivex Therapeutics Ltd

Enlivex and Mount Sinai Health System Announce Research Collaboration for the Development of Allocetra in Combination with Immune Checkpoint Inhibitors

-- Collaboration aims to evaluate the potential of Allocetra™ in combination with immune-checkpoint inhibitors in solid cancer patients that do not respond to stand-alone checkpoint inhibitor...
22. Februar 2021 08:00 ET | Quelle: Enlivex Therapeutics Ltd

Enlivex Receives Notice of Allowance for Chinese Patent Application Covering Allocetra Immunotherapy

Nes-Ziona, Israel, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased...

Vorherige Seite